TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).

Daniel M Geynisman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.